Perspective Therapeutics Doses First Patients in New Cohort Studies, Maintaining Execution Cadence

What happened

Perspective Therapeutics announced that the first patients have been dosed in new cohorts of its ongoing Phase 1/2a studies for [212Pb]VMT-α-NET in neuroendocrine tumors and [212Pb]PSV359 in solid tumors. This operational milestone, while expected after the February 2026 capital raise, confirms that the company is converting its ~$175M gross offering into clinical progress. However, the news lacks any efficacy data—the critical catalyst for a re-rating remains the pending readouts from Cohort 2 and Cohort 3, which the DeepValue report identified as the make-or-break event by August 2026. The filing does not alter the base case that CATX must deliver a confirmed ORR step-up to justify its current valuation.

Implication

The first patient dosing confirms that CATX is deploying its recent equity capital to advance trials, which supports the operational leg of the thesis. However, with interim efficacy still pending for the majority of Cohort 2 and all of Cohort 3, the stock remains a binary event-driven play. Investors should continue to monitor for cohort-complete ORR data—particularly at the higher Cohort 3 dose. Without a demonstrated step-up in efficacy relative to the previous 39% ORR, the upside case weakens. The current price (~$5.28) embeds optimism that may not be justified until definitive readouts arrive. We maintain a WAIT rating with a re-assessment window by August 2026, and would consider adding only if efficacy exceeds 45% ORR with durable responses and no new safety signals.

Thesis delta

The thesis previously hinged on the company converting its ~$175M raise into trial execution; the dosing announcement provides weak confirmation of that conversion but does not alter the fundamental uncertainty around efficacy. The delta is neutral to slightly positive: it reduces a small risk of delayed enrollment but does not change the expected value of the program, which remains contingent on the cohort-complete data. The key valuation drivers—Cohort 2/3 efficacy and regulatory clarity—are unchanged.